aibio.space M&A & Licensing Desk
Mergers, acquisitions, tender offers, reverse mergers, SPAC deals, asset sales and Schedule 13D activism.
Sources: SEC filings and company press releases, with wires, trade press and court dockets used as leads and confirmed against a filing. The desk follows our editorial standards. 248 stories so far.
Latest stories
- InMed sets November 5 record date for CVRs tied to Mentari merger
- Rallybio declares estimated $82.7 million cash distribution tied to Avenzo merger
- Skye Bioscience files preliminary proxy for its Redx Pharma acquisition
- Bolt Biotherapeutics buys Prana Therapies and raises $120 million
- Biotech reverse mergers reach highest count since 2021 as PIPEs return, J.P. Morgan says
- Merck KGaA agrees to buy Silence Therapeutics for $20 per ADS to get PV drug divesiran
- MiMedx and Sanara MedTech receive FTC Second Request on merger
- MiMedx and Sanara receive FTC Second Request on proposed merger
- Rallybio holders to own 2.8% of the combined company in Avenzo reverse merger
- Aditxt unit Ignite Proteomics and Copley Acquisition Corp end SPAC merger deal
- Aibotics completes purchase of PlayJamaica robotics and drone assets
- Eton Pharmaceuticals pays $10.0 million upfront for US rights to Aquestive's Libervant
- LogicMark completes merger, holders receive $1.31 a share in cash
- Pulmatrix stockholders to vote October 26, 2026 on Eos SENOLYTIX merger
- Senti Biosciences adjourns annual meeting to seek more votes for merger proposal
- Alaunos Therapeutics acquires Velaris, closes $350 million private placement
- Passage Bio holders would keep about 6% in Remix reverse merger, vote Nov 5
- Boundless Bio files S-4 for Serapha merger; partner later reports early SERP-01 data
- Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash
- Jasper Therapeutics offers $0.324 per warrant to buy back up to 12,345,707 warrants
- Hepion acquires Gravitas Life Sciences in a related party deal
- Adia Med agrees to sell 30% of Adia Labs to QCM Biologics for $1,500,000
- BeyondSpring completes sale of subsidiary holding China unit Bulin for non-cash consideration
- BeyondSpring sells BeyondSpring Ltd. for trial data rights instead of cash
- ENDRA amends merger agreement with ASP Isotopes and Renergen
- SpyGlass buys lens maker Advanced Vision Science from Santen for about $13 million
- Mangoceuticals unit MangoRx IP gets $2.5 million commitment, receives $1.75 million
- Chemomab amends domestication merger terms ahead of Scipher Medicine deal
- Lexeo completes Mantle Therapeutics deal for $5,300,000 cash plus $3,000,000 in stock
- Lifecore Biomedical agrees to $6.28 a share cash sale to Webster Equity Partners
- Glucotrack CEO outlines Lokahi priorities for LT-100 and the ai² platform
- Zymeworks completes Theravance Biopharma acquisition, with $350 million in senior secured notes
- Impact BioMedical reports Zoar F-4 filing in business combination
- Aethlon to merge with North Immunology in an all-stock deal
- Tarsus Pharmaceuticals completes Alkeus acquisition with $270,000,000 in cash up front
- Clearmind Medicine agrees to buy 51% of Charging Robotics for $2.5 million
- International Stem Cell completes sale of Lifeline Cell Technology to ATCC
- Cyclerion (now Korsana Biosciences) shareholders approve merger issuance and 1-for-7 reverse split
- Elutia completes SimpliDerm business sale to Cellution Biologics, receives $7.7 million
- Arbutus plans US$230 million Dutch auction tender offer for its shares
aibio